| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/11/2008 | US20080221079 Pharmaceutical composition of quetiapine fumarate |
| 09/11/2008 | US20080221078 Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia |
| 09/11/2008 | US20080221077 Ansamycin formulations and methods of use thereof |
| 09/11/2008 | US20080221076 Crystalline Sodium Salt of Cephalosporin Antibiotic |
| 09/11/2008 | US20080221075 To treat obesity or diabetes; reduction of serum cholesterol and the treatment of atherosclerosis |
| 09/11/2008 | US20080221074 Drug Screen and Treatment Method |
| 09/11/2008 | US20080221073 Nitrooxy Derivatives of Glucocorticoids |
| 09/11/2008 | US20080221072 Fatty Acid Modified Forms of Glucocorticoids |
| 09/11/2008 | US20080221071 Comprises lumisterol and tachysterol, for topical administration |
| 09/11/2008 | US20080221070 Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
| 09/11/2008 | US20080221069 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders |
| 09/11/2008 | US20080221068 Oral administration of an amino acid with a N-terminal blocking group and a N-(2-boric pyrrolyl) group attached to the carboxyl group; anticarcinogenic, antiproliferative, antimetastasis agents for lung, kidney, pancreatic, breast, and colorectal cancers; angiogenesis inhibition |
| 09/11/2008 | US20080221066 Agmatine or aminoguanidine and dextran hydroxypolymer, Tc-99m radionuclide, Farmorubicine anticancer drug, Tamoxifen; intravesically, regiolocally, peritoneally, intratumorally, systemically or intravenously administrable |
| 09/11/2008 | US20080221065 Pharmaceutical formulations; epothilone and mannitol or a cyclodextrin parenteral administration in the form of an infusion concentrate or lyophilised composition |
| 09/11/2008 | US20080221064 Pharmaceutical composition for dry eye, which remains on the cornea and exhibits a humectant effect for a longer period |
| 09/11/2008 | US20080221063 4-(3-Chloro-1H-indole-6-sulfonyl)-1-[1-(1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl)-piperidin-4-ylmethyl]-6-oxo-piperazine-2-carboxylic acid for example; antithrombotic and anticoagulant; synthesis; combination therapy |
| 09/11/2008 | US20080221062 Non-steroidal anti-inflammatory drugs bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region and disease-modifying anti-rheumatic drugs; salicylic acid, aspirin, mefenamic acid, tolfenamic acid; arthritis, suppress inflammation and pain; parenteral, topical |
| 09/11/2008 | US20080221061 Lung-Targeted Drugs |
| 09/11/2008 | US20080221060 Therapeutic Compounds |
| 09/11/2008 | US20080221059 Novel treatment tool for cancer: rna interference of bcas2 |
| 09/11/2008 | US20080221058 Tumor-Specific Vector for Gene Therapy |
| 09/11/2008 | US20080221057 Gene expression inhibition; drug screening; wnt genes; catenins |
| 09/11/2008 | US20080221056 Early Detection and Prognosis of Colon Cancers |
| 09/11/2008 | US20080221055 Compositions and methods for inhibiting expression of huntingtin gene |
| 09/11/2008 | US20080221054 In vitro; transgenic cells, mammals; kits |
| 09/11/2008 | US20080221053 Oligonucleotide sequences which bind biomolecules such as peptides, hydrophobic molecules and extracellular proteins for diagnosing and treating cardiovascular disorders in mammals; selectively bind coagulation factors, E2F family members, Ang1 or Ang2 |
| 09/11/2008 | US20080221052 Modulation of Wrn-Mediated Telomere-Initiated Cell Signaling |
| 09/11/2008 | US20080221051 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 09/11/2008 | US20080221050 Genetic polymorphisms linked to optic neuropathy including glaucoma and Leber's disease; point mutations; enothelins; angiotensins; gene expression inhibition |
| 09/11/2008 | US20080221049 Free-flowing lyophilized tobramycin formulation |
| 09/11/2008 | US20080221048 Stable, sterile; community-acquired pneumonia or pelvic inflammatory disease |
| 09/11/2008 | US20080221047 Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug |
| 09/11/2008 | US20080221046 Macrolides With Anti-Inflammatory Activity |
| 09/11/2008 | US20080221045 Hepatic Function-Improving Agent |
| 09/11/2008 | US20080221044 Composition for Inhibiting the Onset of Arteriosclerosis and Inhibition Method |
| 09/11/2008 | US20080221034 Canine specific growth hormone releasing hormone |
| 09/11/2008 | US20080221029 Administering a sulfasalazine, a sulfasalazine metabolite, a sulfa-containing compound, a flavone, a flavanone, an isoflavone, a flavanol, a benzoic acid, an indole derivative, a 1,4-Naphthoquinone, a 3-Phenylcoumarin, a 2-phenyl-4-quinoline, a 1-thioflavone, a thioflavin, or a chalcone; lung infections |
| 09/11/2008 | US20080221027 Administrating a composition to artificially increase sarcospan activity in a muscle tissue of the patient; increasing the dystrophin-related complex |
| 09/11/2008 | US20080221025 Use of Trpc Channel for the Treatment of a Cardiovascular Disease |
| 09/11/2008 | US20080221021 Novel Corticotropin-Releasing Factor Receptor 1 (Crfr1) Agonist |
| 09/11/2008 | US20080221018 Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto |
| 09/11/2008 | US20080221017 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration |
| 09/11/2008 | US20080221014 Method of Diagnosing and Treating Glioma |
| 09/11/2008 | US20080220500 Expression vector comprising nucleotide sequences coding lipogenic enzyme for treatment and prevention of cardiovascular, inflammatory, nervous system, gastrointestinal and psychological disorders |
| 09/11/2008 | US20080220454 Using erastin as therapeutic agent in treatment of cell proliferative disorders associated with mutation in ras gene |
| 09/11/2008 | US20080220104 Stimulate the release of cholecystokinin and serotonin into the bloodstream using tryptophan and fatty acids; enables greater weight loss |
| 09/11/2008 | US20080220103 Treating fungal infection on animal epidermis, nail or hair, or in an orifice of an animal using essential oil |
| 09/11/2008 | US20080220102 Solubilsation Products of an Active Ingredient Extract |
| 09/11/2008 | US20080220097 Taken before meals, reduces the appetite, leading to a reduction in body weight |
| 09/11/2008 | US20080220095 Red blood cells loaded with s-nitrosothiol and uses therefor |
| 09/11/2008 | US20080220094 Compositions and methods for the treatment and/or prevention of osteoporosis |
| 09/11/2008 | US20080220092 Overcoming active agent tolerance, which may be experienced from continuous administration, improve patient compliance, and in some cases reducing the amount of drug needed per dose due to advantages of biosynchronization |
| 09/11/2008 | US20080220091 Reduction of reactive oxygen species in chronic wound management |
| 09/11/2008 | US20080220087 Colon cleansing composition and method |
| 09/11/2008 | US20080220084 Combination therapy for alleviating pain-related conditions |
| 09/11/2008 | US20080220080 multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) a core layer comprising a substance having a modulating effect, b) an inner controlling layer which influences the delivery of the substance as modulator |
| 09/11/2008 | US20080220079 Sustained release spherical or non-spherical pellets comprising (a) an active ingredient (b) a wax-like agent, and (c) a spheronizing agent; oral dosage forms; drug such as antivirals, vitamins, NSAIDS, antibiotics, insect growth regulators; dosing flexibility e.g. for animals |
| 09/11/2008 | US20080220078 Pharmaceutical Formulations |
| 09/11/2008 | US20080220077 injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy |
| 09/11/2008 | US20080220076 agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having effective average particle size of less than 2000 nm, with no surfactants or phosphatides |
| 09/11/2008 | US20080220075 Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods making and using such compositions. |
| 09/11/2008 | US20080220074 Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
| 09/11/2008 | US20080220073 The Treatment of Respiratory Diseases |
| 09/11/2008 | US20080220072 Biologic modulations with nanoparticles |
| 09/11/2008 | US20080220071 Aqueous Suspensions of Poorly Water-Soluble and Water-Insoluble Active Ingredients and Drying Powder Produced Therefrom |
| 09/11/2008 | US20080220069 Long Acting Injectable Crystal Formulations of Estradiol Metabolites and Methods of Using Same |
| 09/11/2008 | US20080220068 Treatment and prevention of excessive scarring |
| 09/11/2008 | US20080220067 therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p- ditolylsulfone |
| 09/11/2008 | US20080220066 Anti-Viral Topical Gel Formulations Containing a Diuretic Such as Furosemide and/or a Cardiac Glycoside Such as Digoxin |
| 09/11/2008 | US20080220065 of use thereof for treating foot odor caused by microbial organisms, wherein cupric polyatomic salt is utilized as the active ingredient, preferably in combination with a dispersal agent, and wherein healthy tissue is promoted and foot odor is eliminated. |
| 09/11/2008 | US20080220064 Extended release matrix formulations of morphine |
| 09/11/2008 | US20080220059 Pharmaceutical preparation of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide |
| 09/11/2008 | US20080220058 Method and composition for improving hair growth |
| 09/11/2008 | US20080220057 Therapeutic compounds and methods of use |
| 09/11/2008 | US20080220056 Treatment for liver disease |
| 09/11/2008 | US20080220046 Terpolymers for Controlled Release of Bioactive Agents From Implantable Medical Devices |
| 09/11/2008 | US20080220037 nontoxic and biodegradable organophosphorus compounds, having a high receptivity for stainless steel, aluminum or dental surface and form self-assembling thin films on the surfaces; protective coatings |
| 09/11/2008 | US20080220027 Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
| 09/11/2008 | US20080220007 Ehrlichia canis genes and vaccines |
| 09/11/2008 | US20080220003 C5a Receptor Antagonists |
| 09/11/2008 | US20080220001 Using heterocyclic sulfonamide specific to carbonic anhydrase as therapeutic tools in treatment of tumor disorders |
| 09/11/2008 | US20080219998 Anticoagulant for use in treatment and prevention of thrombosis or thrombin-dependent vaso-occlusive disease; selective reduction of intravascular thromboplastin antecedent activity |
| 09/11/2008 | US20080219996 Modulating expression of bone sialoprotein in non-small cell lung cancer tumor as indicator of progression |
| 09/11/2008 | US20080219990 Compositions and methods for the therapy and diagnosis of breast cancer |
| 09/11/2008 | US20080219988 Polypeptide comprising major histocompatibility complex epitopes for targeting and destroying tumor cells |
| 09/11/2008 | US20080219986 Neisserial protein for use in diagnosis, prevention and treatment of microorganismal infection |
| 09/11/2008 | US20080219977 Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer |
| 09/11/2008 | US20080219975 Vegfr3 inhibitors |
| 09/11/2008 | US20080219973 Using antigalectin-3 immunoglobulin as therapeutic in prevention and treatment of glomerulonephritis, diabetic nephropathy and/or tissue fibrosis |
| 09/11/2008 | US20080219968 Son of sevenless homolog 1 (SOS1) suppressive agent for prevention and treatment of cell proliferative disorders |
| 09/11/2008 | US20080219963 Composition Containing Micronutrients With Improved Anti-Oxidant Activity And The Use Thereof |
| 09/11/2008 | US20080219960 Novel Efficient Production Process for Capsular Polysaccharides of Pathogenic Grampositive Bacteria by Heterologous Expression and Secretion of Complex Polysaccharides in Non-Pathogenic, Non-Invasive Gram-Positive Bacteria |
| 09/11/2008 | US20080219953 Cosmid dna constructs and methods of making and using same |
| 09/11/2008 | US20080219951 Fluid mixture for enhancing implantable drug delivery at body temperature |
| 09/11/2008 | US20080219949 Methods for treating brain cancer using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6 dioxo(3-piperidyl))-isoindoline-1,3-dione |
| 09/11/2008 | US20080219948 Angiogenesis inhibitors; immunomodulators; side effect reduction |
| 09/11/2008 | US20080219936 Skin depigmenting compositions comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent |
| 09/11/2008 | US20080219927 storage stable mixture of methyl trans-4-[3-[6-amino-9-(N-ethyl- beta -D-ribofuranosyluronamide)-9H-purin-2-yl]prop-2-ynyl]cyclohexane carboxylate, water and hydroxypropyl-beta-cyclodextrin, used for myocardial perfusion imaging |
| 09/11/2008 | US20080219924 Imaging, diagnosis and treatment of disease |
| 09/11/2008 | US20080219922 Alzheimer's Disease Imaging Agents |